{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:35:52Z","timestamp":1788568552604,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jtha.2023.09.009","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T02:21:19Z","timestamp":1695176479000},"page":"3508-3510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa"],"prefix":"10.1016","volume":"21","author":[{"given":"Justine H.","family":"Ryu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.09.009_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.09.009_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/hae.13366","article-title":"Type 2N von Willebrand disease: Characterization and diagnostic difficulties","volume":"24","author":"Casonato","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.009_bib3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/jth.15247","article-title":"Von Willebrand disease type 2N: an update","volume":"19","author":"Seidizadeh","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.009_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis","volume":"345","author":"Koster","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.09.009_bib5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCULATIONAHA.118.034532","article-title":"Genome-wide association transethnic meta-analyses identifies novel associations regulating coagulation factor VIII and von Willebrand factor plasma levels","volume":"139","author":"Sabater-Lleal","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.09.009_bib6","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1182\/blood.V77.9.1937.1937","article-title":"The \"Normandy\" variant of von Willebrand disease: characterization of a point mutation in the von Willebrand factor gene","volume":"77","author":"Gaucher","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.09.009_bib7","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1073\/pnas.88.14.6377","article-title":"Expression of von Willebrand factor \"Normandy\": an autosomal mutation that mimics hemophilia A","volume":"88","author":"Tuley","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.09.009_bib8","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.722827","article-title":"von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes","volume":"117","author":"Spiel","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.09.009_bib9","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice","volume":"135","author":"Seth Chhabra","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.09.009_bib10","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood.2020009197","article-title":"Molecular determinants of the factor VIII\/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy","volume":"137","author":"Fuller","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.09.009_bib11","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.rpth.2023.100176","article-title":"Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa","volume":"7","author":"Lissitchkov","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.009_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"XTEND-1 Trial Group. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.009_bib13","series-title":"ALTUVIIIO (efanesoctocog alfa) [package insert]","year":"2023"},{"key":"10.1016\/j.jtha.2023.09.009_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021006119","article-title":"Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study","volume":"6","author":"Lissitchkov","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.09.009_bib15","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:39:24Z","timestamp":1761536364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623007080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1538783623007080"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.09.009","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}